Condition (MeSH)
Syndactyly
ClinicalTrials.gov lists 42 trials for Syndactyly or a narrower condition beneath it. Incyte Corporation has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 42 trials are tagged with Syndactyly itself; the rest are tagged with a narrower condition beneath it.
When did Syndactyly trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 5 |
| 2018 | 2 |
| 2017 | 6 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Syndactyly trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 14 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 5 |
| Observational | 10 |
How many Syndactyly trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 3 |
| Completed | 19 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Syndactyly trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Incyte Corporation | 7 |
| Janssen Research & Development, LLC | 3 |
| National Human Genome Research Institute (NHGRI) | 3 |
| Basilea Pharmaceutica | 2 |
| Eisai Co., Ltd. | 2 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Syndactyly? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Infigratinib | 3 |
| E7090 | 3 |
| Rogaratinib | 2 |
| PEMBROLIZUMAB | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pemigatinib Pill | 6 |
| Gemcitabine/Gemzar | 2 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | 1 |
| Derazantinib 200 mg once daily + atezolizumab 1200 mg | 1 |
| or carboplatin | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Syndactyly trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disease progression | 35 | 3 |
| Abdominal pain | 27 | 5 |
| Urinary tract infection | 27 | 4 |
| Acute kidney injury | 20 | 4 |
| General physical health deterioration | 20 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Syndactyly? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations. | Genetics in medicine : official journal of the American College of Medical Genetics | 2021 | Yes |
| Hyaluronic acid scaffold for skin defects in congenital syndactyly release surgery: a novel technique based on the regenerative model. | The Journal of hand surgery, European volume | 2014 | Yes |
| A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia. | PloS one | 2013 | Yes |
| The open finger technique for the release of syndactyly. | Journal of hand surgery (Edinburgh, Scotland) | 2001 | Yes |
| Confirmation of genetic homogeneity of syndactyly type 1 in an Iranian family. | American journal of medical genetics | 2001 | Yes |
Showing 5 of 17 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Non-syndromic syndactyly | 90025 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Non-syndromic syndactyly | 90025 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.